Metachronous medulloblastoma and glioblastoma: Implications for clinical and technical aspects of re-irradiation

Vivek Verma, Rajesh R. Kulkarni, Abhijeet R. Bhirud, Nathan R. Bennion, Rodney D McComb, Chi Lin

Research output: Contribution to journalArticle

Abstract

A seven-year-old male underwent surgical resection and chemoradiation for average riskmedulloblastoma; twelve years later, the presence of a necrotic and infiltrative mass inthe same area and invading the brainstem prompted a subtotal resection. Pathology wasindicative of glioblastoma. He was then treated with concurrent temozolomide and usingbiologically effective dose calculations for gross residual tumor tissue in the brainstemas well as brainstem tolerance, a radiotherapy dose of 3750 cGy was chosen, fractionatedin twice-daily fractions of 125 cGy each. The gross tumor volume was expanded with a5 mm margin to the planning target volume, which was also judiciously subtracted fromthe normal brainstem. He completed his radiotherapy course with subsequent imagingfree of residual tumor and continued adjuvant temozolomide and remains under follow-up surveillance. This case underscores the rarity of metachronous medulloblastoma andglioblastoma, of which only five known cases heretofore have been described. We discussthe technicalities of radiotherapy planning in this patient, including common hurdles forradiation oncologists in similar patients.

Original languageEnglish (US)
Pages (from-to)84-89
Number of pages6
JournalReports of Practical Oncology and Radiotherapy
Volume21
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

temozolomide
Medulloblastoma
Glioblastoma
Brain Stem
Radiotherapy
Residual Neoplasm
Tumor Burden
Pathology
Re-Irradiation

Keywords

  • Brainstem tolerance
  • Glioblastoma
  • Medulloblastoma
  • Re-irradiation
  • Toxicity

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Metachronous medulloblastoma and glioblastoma : Implications for clinical and technical aspects of re-irradiation. / Verma, Vivek; Kulkarni, Rajesh R.; Bhirud, Abhijeet R.; Bennion, Nathan R.; McComb, Rodney D; Lin, Chi.

In: Reports of Practical Oncology and Radiotherapy, Vol. 21, No. 1, 01.01.2016, p. 84-89.

Research output: Contribution to journalArticle

@article{1cbfd5d0bf7548c9a7b562fdec2e4c12,
title = "Metachronous medulloblastoma and glioblastoma: Implications for clinical and technical aspects of re-irradiation",
abstract = "A seven-year-old male underwent surgical resection and chemoradiation for average riskmedulloblastoma; twelve years later, the presence of a necrotic and infiltrative mass inthe same area and invading the brainstem prompted a subtotal resection. Pathology wasindicative of glioblastoma. He was then treated with concurrent temozolomide and usingbiologically effective dose calculations for gross residual tumor tissue in the brainstemas well as brainstem tolerance, a radiotherapy dose of 3750 cGy was chosen, fractionatedin twice-daily fractions of 125 cGy each. The gross tumor volume was expanded with a5 mm margin to the planning target volume, which was also judiciously subtracted fromthe normal brainstem. He completed his radiotherapy course with subsequent imagingfree of residual tumor and continued adjuvant temozolomide and remains under follow-up surveillance. This case underscores the rarity of metachronous medulloblastoma andglioblastoma, of which only five known cases heretofore have been described. We discussthe technicalities of radiotherapy planning in this patient, including common hurdles forradiation oncologists in similar patients.",
keywords = "Brainstem tolerance, Glioblastoma, Medulloblastoma, Re-irradiation, Toxicity",
author = "Vivek Verma and Kulkarni, {Rajesh R.} and Bhirud, {Abhijeet R.} and Bennion, {Nathan R.} and McComb, {Rodney D} and Chi Lin",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.rpor.2015.10.002",
language = "English (US)",
volume = "21",
pages = "84--89",
journal = "Reports of Practical Oncology and Radiotherapy",
issn = "1507-1367",
publisher = "Elsevier Urban and Partner sp. z o.o.",
number = "1",

}

TY - JOUR

T1 - Metachronous medulloblastoma and glioblastoma

T2 - Implications for clinical and technical aspects of re-irradiation

AU - Verma, Vivek

AU - Kulkarni, Rajesh R.

AU - Bhirud, Abhijeet R.

AU - Bennion, Nathan R.

AU - McComb, Rodney D

AU - Lin, Chi

PY - 2016/1/1

Y1 - 2016/1/1

N2 - A seven-year-old male underwent surgical resection and chemoradiation for average riskmedulloblastoma; twelve years later, the presence of a necrotic and infiltrative mass inthe same area and invading the brainstem prompted a subtotal resection. Pathology wasindicative of glioblastoma. He was then treated with concurrent temozolomide and usingbiologically effective dose calculations for gross residual tumor tissue in the brainstemas well as brainstem tolerance, a radiotherapy dose of 3750 cGy was chosen, fractionatedin twice-daily fractions of 125 cGy each. The gross tumor volume was expanded with a5 mm margin to the planning target volume, which was also judiciously subtracted fromthe normal brainstem. He completed his radiotherapy course with subsequent imagingfree of residual tumor and continued adjuvant temozolomide and remains under follow-up surveillance. This case underscores the rarity of metachronous medulloblastoma andglioblastoma, of which only five known cases heretofore have been described. We discussthe technicalities of radiotherapy planning in this patient, including common hurdles forradiation oncologists in similar patients.

AB - A seven-year-old male underwent surgical resection and chemoradiation for average riskmedulloblastoma; twelve years later, the presence of a necrotic and infiltrative mass inthe same area and invading the brainstem prompted a subtotal resection. Pathology wasindicative of glioblastoma. He was then treated with concurrent temozolomide and usingbiologically effective dose calculations for gross residual tumor tissue in the brainstemas well as brainstem tolerance, a radiotherapy dose of 3750 cGy was chosen, fractionatedin twice-daily fractions of 125 cGy each. The gross tumor volume was expanded with a5 mm margin to the planning target volume, which was also judiciously subtracted fromthe normal brainstem. He completed his radiotherapy course with subsequent imagingfree of residual tumor and continued adjuvant temozolomide and remains under follow-up surveillance. This case underscores the rarity of metachronous medulloblastoma andglioblastoma, of which only five known cases heretofore have been described. We discussthe technicalities of radiotherapy planning in this patient, including common hurdles forradiation oncologists in similar patients.

KW - Brainstem tolerance

KW - Glioblastoma

KW - Medulloblastoma

KW - Re-irradiation

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84953432461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953432461&partnerID=8YFLogxK

U2 - 10.1016/j.rpor.2015.10.002

DO - 10.1016/j.rpor.2015.10.002

M3 - Article

C2 - 26900364

AN - SCOPUS:84953432461

VL - 21

SP - 84

EP - 89

JO - Reports of Practical Oncology and Radiotherapy

JF - Reports of Practical Oncology and Radiotherapy

SN - 1507-1367

IS - 1

ER -